In the production of veterinary topical ointments and liniments, camphor ointment grade API is processed as a dispersed crystalline phase in oleaginous bases rather than as a simple dissolved solute. The material as supplied consists of waxy, translucent crystals with a melting point of 174–177 °C and a significant sublimation tendency at ambient temperature. This physical profile requires size reduction on a chilled three-roll mill with a gap setting of 25–50 μm, followed by dispersion into white petrolatum or anhydrous lanolin bases heated to 60–65 °C. Homogenization is performed in a vacuum emulsifier with a scraped-surface agitator, and the batch is cooled under continuous agitation to 25 °C to prevent camphor from recrystallizing as coarse surface crystals. The terminal ointment is tested for grittiness and for assay by gas chromatography against a camphor reference standard. Release testing for non-sterile cutaneous products follows Ph. Eur. 5.1.4; the preparation must also be free from Pseudomonas aeruginosa in 1 g and must not contain more than 10² CFU/g total aerobic microbial count. Incompatibilities include strong oxidizing agents and hypochlorite-based cleaning residues, which slowly degrade the ketone group. Published data for this specific configuration is limited, so batch-specific homogenization time and cooling ramp must be qualified on the production vessel.

For ointment batches, the final particle size of camphor crystals is controlled by microscopic examination or optical microscopy against a 100 μm upper limit. Overmilling is avoided because excessive mechanical energy raises the temperature at the roll surface and accelerates camphor loss by sublimation. The milled dispersion is held under a nitrogen blanket in closed transfer lines when the batch is moved to the filling line. Stainless steel contact surfaces are preferred, because camphor can penetrate and soften certain elastomeric gaskets and hoses. Filling is performed at 20–25 °C into collapsible aluminum tubes or white polypropylene jars with induction-sealed closures. The headspace is minimized to reduce camphor migration into closure liners.

Why Do Injectable Veterinary Formulations Require Non-Aqueous Solvent Systems?

Sterile injectable formulations containing camphor are constrained by the low aqueous solubility of the API, which is approximately 1.2 mg/mL at 25 °C. Aqueous vehicles alone cannot deliver a clinically useful dose without precipitation at the injection site, so non-aqueous or mixed solvent systems are required. Typical development work evaluates ethyl oleate, medium-chain triglycerides, benzyl alcohol, or propylene glycol as the primary solvent. Dissolution is carried out in a closed stainless steel or glass-lined vessel at 40–50 °C under nitrogen to suppress oxidative degradation of the vehicle and to limit camphor evaporation. The resulting solution is filtered through a sterilizing-grade 0.22 μm PVDF membrane. Filter compatibility must be verified because camphor can plasticize membrane supports or housing components during prolonged exposure. Aseptic filling is performed under ISO 14644-1 Class 5 conditions into amber Type I borosilicate vials with PTFE-coated butyl rubber stoppers. The finished injection is tested according to USP <788> for subvisible particulate matter; for small-volume injectable preparations the limits are not more than 6000 particles per container at ≥10 μm and not more than 600 particles per container at ≥25 μm. Bacterial endotoxin testing follows USP <85>, with the endotoxin limit calculated from the intended dose volume and species-specific route of administration. Terminal steam sterilization is generally not applied to oily camphor injections because the thermal exposure can alter the vehicle and redistribute camphor; aseptic processing is therefore the common clinical and regulatory approach. Published data for specific injectable camphor monographs in modern veterinary pharmacopoeias is limited, so each non-aqueous vehicle must be qualified by phase stability, filter compatibility, and syringeability studies before manufacture.

Water-based injectable development should not proceed without a validated ternary co-solvent phase diagram. If a small amount of water is introduced into an ethanol or propylene glycol vehicle, camphor may precipitate as fine crystals that are not visible on gross inspection. Dynamic light scattering or particle counting is used to detect this failure mode. The presence of camphor crystals after dilution with plasma or tissue fluid can cause local irritation and inconsistent pharmacokinetics. For this reason, injectable camphor products are usually formulated as single-phase oily solutions or as solubilized non-aqueous concentrates. Syringeability is measured with a 21-gauge needle at 25 °C using a texture analyzer or calibrated syringe pump, and the maximum permissible glide force is defined per container-closure system. Materials of construction for mixing vessels and filling needles are selected from 316L stainless steel or glass, with polytetrafluoroethylene seals replacing silicone rubber where direct contact occurs.

Tablet and Capsule Manufacturing Boundaries When the API Sublimes Below Drying Temperature

Camphor powder for oral solid dosage forms presents a compressibility boundary and a volatility boundary that are not encountered with most crystalline APIs. The substance has poor plastic deformation and high elastic recovery during decompression, so direct compression is usually unsuccessful. Wet granulation is the preferred route. Camphor is dissolved or dispersed in an ethanolic binder solution containing 3–5 % w/w povidone K30, then granulated with lactose monohydrate and pregelatinized starch in a high-shear granulator. The wet mass is dried in a fluid-bed dryer with inlet air temperature not exceeding 40 °C to keep the granule bed temperature below 30 °C. Loss on drying is controlled to ≤ 2.0 % as determined by USP <731>. Drying above this window causes measurable camphor loss through sublimation and produces granule assay non-uniformity. The dried granulation is milled through a 1.0 mm screen and blended in a bin blender at 8–12 rpm for 15–20 min. Compression is performed on a rotary tablet press with precompression force of 2–4 kN and main compression force of 8–15 kN, depending on tooling diameter. Tablet hardness is held between 40 N and 70 N, and friability is required to be ≤ 1.0 % according to USP <1216>. Dissolution testing uses USP <711> Apparatus 2 at 75 rpm in 0.1 N hydrochloric acid with 0.5 % sodium lauryl sulfate, with sealed vessels to correct for camphor evaporation. Content uniformity is evaluated by USP <905> with an acceptance value AV ≤ 15.0.

For hard gelatin capsules, the primary difficulty is the high vapor pressure of camphor and its tendency to migrate into the capsule shell. Filling rooms are maintained at 20–22 °C and 40–45 % relative humidity. A tamping-pin or dosator-type capsule filler is used, because flood-fed auger systems can compact the low-density camphor blend and cause weight variability. The fill formulation typically contains pregelatinized starch and microcrystalline cellulose, with colloidal silicon dioxide at 0.2–0.5 % w/w to improve flow. Magnesium stearate is kept below 1.0 % w/w because camphor can compete for surface adsorption sites and alter dissolution. Capsules are packaged in aluminum foil blisters with desiccant, and the packaging is checked for camphor sublimation loss after storage at 40 °C/75 % RH for 6 months according to ICH Q1A(R2). LDPE bottles are not recommended without an aluminum foil liner because camphor can permeate low-density polyethylene and result in mass loss.

If Medicated Premix Carriers Are Heated Above 40 °C, Camphor Migration Becomes the Dominant Loss Mechanism

Dry oral powders and medicated premixes containing camphor differ from conventional antibiotics or antiparasitic powders because the API is volatile and mobile within the solid matrix. The carrier is typically milled corn cob, rice hull, or lactose granules with a particle size range of 300–600 μm. Mixing is performed in a low-shear ribbon blender at 15–25 rpm with a fill level of 40–70 %. The mixing time is determined by blend uniformity sampling from at least 10 locations, and acceptance is set at relative standard deviation ≤ 5.0 % according to the FDA Guidance for Industry on Powder Blends. High-shear mixing is not used because camphor particles fracture and increase surface area, accelerating sublimation. After blending, the premix is discharged through a closed transfer system into kraft paper bags with an inner aluminum foil laminate. Storage is controlled below 30 °C. If the premix is incorporated into pelleted feed, the pellet die temperature must remain below 60 °C; above this threshold camphor migrates into the headspace of the conditioner and post-pelleting assay losses become measurable. The final premix is assayed by HPLC or GC-FID using a validated extraction method. Residual solvent testing for ethanol, if used during granulation, follows VICH GL18. The major incompatibility in premix systems is the presence of fine mineral carriers such as bentonite or activated charcoal, which can bind camphor irreversibly and reduce recovery during extraction.

Granular formulations intended for oral administration to calves or swine are produced by low-shear wet granulation or by spraying an ethanolic camphor solution onto sugar spheres in a coating pan. The coating pan is operated at 8–12 rpm with inlet air below 35 °C. Ethanol is removed under reduced pressure to prevent residual solvent levels above the limit defined in the product specification. The coated granules are sieved through a 1.25 mm screen and dusted with talc to reduce static adhesion. The finished granules are filled into unit-dose sachets made of paper/PE/aluminum foil/PE laminate. Stability testing at 40 °C/75 % RH for 6 months is used to detect camphor loss through seal failure. Sealing integrity is tested by vacuum leak test or methylene blue dye penetration, depending on the container type. The powder blend must not be stored in open containers in the production area for more than 2 h, because camphor sublimation losses at ambient temperature become detectable by assay decrease after that interval.

Aqueous oral drench solutions formulated with camphor require a binary or ternary co-solvent system because the API precipitates when the solution is diluted with water. A typical vehicle contains ethanol 10–20 % v/v and propylene glycol 20–40 % v/v, with the balance purified water. Camphor is dissolved in the ethanol/propylene glycol phase at 25–30 °C in a closed jacketed vessel, then water is added under controlled agitation to avoid localized precipitation. The solution is cooled to 5 °C for 48 h as a physical stability challenge; any crystal formation at this stage requires reformulation or an increase in co-solvent ratio. Viscosity is measured at 25 °C with a Brookfield RV spindle 2 at 50 rpm; the target is below 50 mPa·s to allow accurate delivery from a drench gun. pH is maintained between 5.0 and 7.0, and antimicrobial preservation is validated according to Ph. Eur. 5.1.3. Sodium benzoate at 0.1 % w/v or potassium sorbate at 0.1 % w/v is selected when the formulation contains water. The finished solution is filled into amber polyethylene terephthalate bottles sealed with polypropylene caps and EPE liners. Accelerated stability testing follows ICH Q1A(R2) at 40 °C/75 % RH for 6 months, with assay, pH, preservative content, and visual appearance monitored at intervals.

For oral drench use in ruminants, the dose volume is calibrated using a drench gun that delivers a fixed volume per stroke. The product is packaged with a draw-off adapter that prevents contamination of the bulk solution during repeated use. The oral solution must be protected from freezing during transport, because phase separation can occur below 0 °C and may not fully redissolve on warming. Incompatibility with polycarbonate dosing syringes is noted, as camphor may stress-crack polycarbonate after repeated contact. Polypropylene or stainless steel dosing equipment is preferred.

For ethanol-based veterinary liniments and udder rubs intended for external skin application, a low-viscosity single-phase vehicle is prepared with ethanol 70 % v/v, camphor 0.5–2.0 % w/w, and a small amount of propylene glycol to reduce skin drying. The solution is mixed at 20–25 °C in a closed stainless steel vessel to minimize evaporative loss. Viscosity is controlled below 50 mPa·s at 25 °C using a Brookfield RV viscometer spindle 2 at 50 rpm. The product is filtered through a 10 μm polypropylene cartridge before filling. Packaging is typically 140 mL high-density polyethylene bottles with fluoropolymer-lined spray caps or plug seals. The spray nozzle orifice is 0.5 mm to deliver a fine mist without clogging. The final product is visually inspected for clarity after 48 h at 5 °C and again after three freeze-thaw cycles between -5 °C and 25 °C. A clear solution with no sediment is required. The ethanol content is verified by gas chromatography, and the camphor assay is determined against a known reference standard. Because the product is alcohol-based, flameproof mixing equipment and explosion-rated electrical fittings are required in the manufacturing area. The main incompatibility is with strong oxidizing agents; contact with chlorinated cleaning agents must be prevented because residual chlorine can degrade the ketone structure of camphor. Published data for modern registered camphor liniment formulas is limited, so the specific ethanol-to-water ratio and camphor concentration must be justified by formulation development and stability data for the intended target species.